NK cells are increased in patients with XLT and WAS
Patient . | Age, mo . | ALC, × 109/L . | CD3+, %* . | CD19+, %* . | CD16+CD56+CD3−, %* . | CD16+CD56+CD3−† . |
|---|---|---|---|---|---|---|
| XLT phenotype | ||||||
| W2 | 141 | 1.282 | 31.3‡ | 12.6 | 50.6§ | 6-27 |
| W3 | 109 | 3.580 | 48.6‡ | 8.4‡ | 45.5§ | 4-26 |
| W7 | 160 | 1.432 | 67.5 | 15.1 | 12.5 | 6-27 |
| W8 | 40 | 2.770 | 54.1 | 13.3‡ | 18.6 | 4-23 |
| W10 | 76 | 2.140 | 68.3 | 16.1 | 9.1 | 4-26 |
| W11 | 103 | 3.855 | 60.4 | 22.4 | 10.2 | 4-26 |
| W12 | 128 | 1.760 | 58.8 | 14.1 | 18.6 | 6-27 |
| W18 | 85 | 4.368 | 79.1 | 15.1 | 7.6 | 4-26 |
| W19 | 91 | 2.080 | 53.5‡ | 15.9 | 29.9§ | 4-26 |
| WAS phenotype | ||||||
| W4 | 15 | 2.730 | 58.6 | 25.5 | 7.6 | 3-16 |
| W5 | 19 | 1.426‡ | 74.1 | 12.6‡ | 10.2 | 3-16 |
| W9 | 58 | 1.612‡ | 54.0 | 11.6‡ | 31.7§ | 4-23 |
| W13 | 84 | 1.526 | 68.8 | 14.8 | 9.7 | 4-26 |
| W15 | 17 | 10.834 | 32.5‡ | 43.0§ | 13.5 | 3-16 |
| W22 | 102 | 2.600 | 50.5‡ | 4.5‡ | 28.0§ | 4-26 |
Patient . | Age, mo . | ALC, × 109/L . | CD3+, %* . | CD19+, %* . | CD16+CD56+CD3−, %* . | CD16+CD56+CD3−† . |
|---|---|---|---|---|---|---|
| XLT phenotype | ||||||
| W2 | 141 | 1.282 | 31.3‡ | 12.6 | 50.6§ | 6-27 |
| W3 | 109 | 3.580 | 48.6‡ | 8.4‡ | 45.5§ | 4-26 |
| W7 | 160 | 1.432 | 67.5 | 15.1 | 12.5 | 6-27 |
| W8 | 40 | 2.770 | 54.1 | 13.3‡ | 18.6 | 4-23 |
| W10 | 76 | 2.140 | 68.3 | 16.1 | 9.1 | 4-26 |
| W11 | 103 | 3.855 | 60.4 | 22.4 | 10.2 | 4-26 |
| W12 | 128 | 1.760 | 58.8 | 14.1 | 18.6 | 6-27 |
| W18 | 85 | 4.368 | 79.1 | 15.1 | 7.6 | 4-26 |
| W19 | 91 | 2.080 | 53.5‡ | 15.9 | 29.9§ | 4-26 |
| WAS phenotype | ||||||
| W4 | 15 | 2.730 | 58.6 | 25.5 | 7.6 | 3-16 |
| W5 | 19 | 1.426‡ | 74.1 | 12.6‡ | 10.2 | 3-16 |
| W9 | 58 | 1.612‡ | 54.0 | 11.6‡ | 31.7§ | 4-23 |
| W13 | 84 | 1.526 | 68.8 | 14.8 | 9.7 | 4-26 |
| W15 | 17 | 10.834 | 32.5‡ | 43.0§ | 13.5 | 3-16 |
| W22 | 102 | 2.600 | 50.5‡ | 4.5‡ | 28.0§ | 4-26 |
All patients with WAS and 2 patients with XLT (W12 and W8) were treated intravenously with immunoglobulins; patients W4 and W13 were treated with 2 mg/kg and 0.5 mg/kg prednisone daily, respectively. ALC indicates absolute lymphocyte count.
Percentages of positive cells for CD3+, CD19+, and CD16+CD56+CD3− were evaluated using immunofluorescence and cytofluorometric analysis.
Age-related normal values of the percentages of CD16+CD56+/CD3− cells (5th and 95th percentiles).
Values below the 5th percentile for age-related normal values.28
Values above the 95th percentile for age-related normal values.28